Crossmark Global Holdings’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $340K | Buy |
1,044
+26
| +3% | +$8.48K | 0.01% | 1043 |
|
|
2025
Q1 | $275K | Buy |
+1,018
| New | +$275K | ﹤0.01% | 1127 |
|
|
2024
Q4 | – | Sell |
-914
| Closed | -$251K | – | 1250 |
|
|
2024
Q3 | $251K | Sell |
914
-4
| -0.4% | -$1.1K | ﹤0.01% | 1149 |
|
|
2024
Q2 | $223K | Buy |
+918
| New | +$223K | ﹤0.01% | 1194 |
|
|
2024
Q1 | – | Sell |
-1,066
| Closed | -$204K | – | 1326 |
|
|
2023
Q4 | $204K | Buy |
+1,066
| New | +$204K | ﹤0.01% | 1246 |
|
|
2023
Q3 | – | Sell |
-1,062
| Closed | -$211K | – | 1261 |
|
|
2023
Q2 | $211K | Sell |
1,062
-72
| -6% | -$14.3K | ﹤0.01% | 1233 |
|
|
2023
Q1 | $227K | Buy |
1,134
+107
| +10% | +$21.4K | 0.01% | 1170 |
|
|
2022
Q4 | $244K | Sell |
1,027
-67
| -6% | -$15.9K | 0.01% | 1101 |
|
|
2022
Q3 | $219K | Buy |
+1,094
| New | +$219K | 0.01% | 1135 |
|
|
2018
Q3 | – | Sell |
-2,059
| Closed | -$203K | – | 1591 |
|
|
2018
Q2 | $203K | Sell |
2,059
-310
| -13% | -$30.6K | 0.01% | 1531 |
|
|
2018
Q1 | $282K | Sell |
2,369
-659
| -22% | -$78.4K | 0.01% | 1317 |
|
|
2017
Q4 | $385K | Buy |
3,028
+59
| +2% | +$7.5K | 0.01% | 1191 |
|
|
2017
Q3 | $349K | Buy |
+2,969
| New | +$349K | 0.01% | 1208 |
|
|
2016
Q3 | $349K | Buy |
+2,969
| New | +$349K | 0.01% | 1208 |
|